Sectors
LEGN
Legend Biotech Corporation
19.86
2 x 14.22
2 x 25.72
bid
ask
-
0.02
0.08%
10:29 AM
timesize
| Ytd | -8.62% | |
| 1y | -42.80% |
19.71
day range
20.05
16.24
52 week range
37.50
| Open | 19.80 | Prev Close | 19.88 | Low | 19.71 | High | 20.05 | Mkt Cap | 3.86B |
| Vol | 232.21K | Avg Vol | 2.73M | EPS | -0.50 | P/E | N/A | Forward P/E | 18.41 |
| Beta | 0.37 | Short Ratio | 6.25 | Inst. Own | 56.86% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-11 | 50-d Avg | 23.44 | 200-d Avg | 23.37 | 1yr Est | 49.25 |
| Income Statement | |||
| Total Revenue | 387.50M | ||
| Revenues (USD) | 387.50M | ||
| Cost of Revenue | 137.40M | ||
| Gross Profit | 250.10M | ||
| Operating Expenses | 192.40M | ||
| Research and Development Expense | 96.00M | ||
| Selling, General and Administrative Expense | 96.40M | ||
| Operating Income | 57.70M | ||
| Interest Expense | 5.80M | ||
| Income Tax Expense | 22.30M | ||
| Net Income | 33.20M | ||
| Net Income Common Stock | 33.20M | ||
| Net Income Common Stock (USD) | 33.20M | ||
| Consolidated Income | 33.20M | ||
| Earnings per Basic Share | 0.18 | ||
| Earnings per Basic Share (USD) | 0.18 | ||
| Earnings per Diluted Share | 0.18 | ||
| Earning Before Interest & Taxes (EBIT) | 61.30M | ||
| Earning Before Interest & Taxes (USD) | 61.30M | ||
| Weighted Average Shares | 371.48M | ||
| Balance Sheet | |||
| Cash and Equivalents | 964.60M | ||
| Cash and Equivalents (USD) | 964.60M | ||
| Current Assets | 1.23B | ||
| Property, Plant & Equipment Net | 448.20M | ||
| Total Assets | 1.75B | ||
| Debt Current | 168.20M | ||
| Total Debt | 278.20M | ||
| Current Liabilities | 403.60M | ||
| Debt Non-Current | 110.00M | ||
| Total Liabilities | 521.30M | ||
| Shareholders Equity | 1.23B | ||
| Shareholders Equity (USD) | 1.23B | ||
| Assets Non-Current | 523.50M | ||
| Total Debt (USD) | 278.20M | ||
| Deferred Revenue | 700.00K | ||
| Inventory | 41.50M | ||
| Liabilities Non-Current | 117.70M | ||
| Trade and Non-Trade Payables | 199.90M | ||
| Tax Liabilities | 33.70M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 11.70M | ||
| Net Cash Flow from Financing | 167.70M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 26.50M | ||
| Capital Expenditure | -7.50M | ||
| Net Cash Flow - Business Acquisitions and Disposals | -13.10M | ||
| Issuance (Purchase) of Equity Shares | 212.60M | ||
| Issuance (Repayment) of Debt Securities | -44.90M | ||
| Net Cash Flow from Investing | -120.00M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -99.40M | ||
| Net Cash Flow from Operations | -20.90M | ||
| Effect of Exchange Rate Changes on Cash | -300.00K | ||
| Share Based Compensation | 17.40M | ||